207 related articles for article (PubMed ID: 26941185)
1. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
Crit Rev Toxicol; 2016 Jul; 46(6):477-89. PubMed ID: 26941185
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
[TBL] [Abstract][Full Text] [Related]
3. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
Onakpoya IJ; Heneghan CJ; Aronson JK
Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1328-1337. PubMed ID: 28691251
[TBL] [Abstract][Full Text] [Related]
6. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
[TBL] [Abstract][Full Text] [Related]
7. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
[TBL] [Abstract][Full Text] [Related]
8. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.
Arnaiz JA; Carné X; Riba N; Codina C; Ribas J; Trilla A
Eur J Clin Pharmacol; 2001 Apr; 57(1):89-91. PubMed ID: 11372600
[TBL] [Abstract][Full Text] [Related]
9. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
[TBL] [Abstract][Full Text] [Related]
10. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
McNaughton R; Huet G; Shakir S
BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems.
Aronson JK
Therapie; 2017 Oct; 72(5):555-561. PubMed ID: 28461037
[TBL] [Abstract][Full Text] [Related]
12. WITHDRAWN--a resource for withdrawn and discontinued drugs.
Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
[TBL] [Abstract][Full Text] [Related]
13. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
14. Withdrawn medicines included in the essential medicines lists of 136 countries.
Charles O; Onakpoya I; Benipal S; Woods H; Bali A; Aronson JK; Heneghan C; Persaud N
PLoS One; 2019; 14(12):e0225429. PubMed ID: 31791048
[TBL] [Abstract][Full Text] [Related]
15. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.
Clarke A; Deeks JJ; Shakir SA
Drug Saf; 2006; 29(2):175-81. PubMed ID: 16454545
[TBL] [Abstract][Full Text] [Related]
16. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision.
Craveiro NS; Lopes BS; Tomás L; Almeida SF
Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381
[TBL] [Abstract][Full Text] [Related]
17. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
Aagaard L; Hallgreen CE; Hansen EH
Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
[TBL] [Abstract][Full Text] [Related]
18. Drug-associated cardiovascular risks: A retrospective evaluation of withdrawn drugs.
Kocadal K; Saygi S; Alkas FB; Sardas S
North Clin Istanb; 2019; 6(2):196-202. PubMed ID: 31297490
[TBL] [Abstract][Full Text] [Related]
19. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
20. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
